Screener
Amphastar Pharmaceuticals AMPH Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Amphastar Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtAndCapitalLeaseObligations.
The source filing: Amphastar Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:50 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001297184-26-000047
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Current portion of operating lease liabilities | 8,800 | 7,928 |
| Total current liabilities | 263,205 | 158,156 |
| Long-term reserve for income tax liabilities | 5,926 | 5,926 |
| Long-term debt, net of current portion and unamortized debt issuance costs | 609,564 | 608,749 |
| Long-term operating lease liabilities, net of current portion | 67,470 | 37,684 |
| Other long-term liabilities | 29,444 | 29,979 |
| Total liabilities | 975,609 | 840,494 |
| Commitments and contingencies (see Note 17) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Amphastar Pharmaceuticals's long-term debt?
- Amphastar Pharmaceuticals (AMPH) reported long-term debt of $609.56M in Q2 2026.
- How has Amphastar Pharmaceuticals's long-term debt changed year-over-year?
- Amphastar Pharmaceuticals's long-term debt increased by 0.3% year-over-year, from $607.73M to $609.56M.
- What is the long-term trend for Amphastar Pharmaceuticals's long-term debt?
- Over 5 years (2020 to 2025), Amphastar Pharmaceuticals's long-term debt has grown at a 77.9% compound annual growth rate (CAGR), from $34.19M to $608.75M.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.
Ask your AI about Amphastar Pharmaceuticals's long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude